ORR with dabrafenib plus trametinib in cancers with 
cancers, nausea, hematological abnormalities, tumor, fatigue, cancer, pyrexia, glioma, headache, sepsis
ROAR, CANCERS, TUMOR, CANCER, GLIOMA, SEPSIS
This figure presents data for the ROAR study (gray) and other studies in adults (blue) and the pediatric population (green). Data are presented for the COMBI-d study (In general, There is an unmet need in the management of rare cancers with Dabrafenib 150 mg twice daily plus trametinib 2 mg once daily was well tolerated in this study, with a clinically acceptable incidence of AEs, dose interruptions and treatment discontinuations. Across all cohorts, the observed safety profile of this combination was consistent with the known safety profile in approved indications of The most frequently reported AEs across all cohorts were pyrexia (54.9%), fatigue (42.2%) and nausea (41.7%). The other AEs noted during the study were largely consistent with what is expected in pre-treated populations with cancer and that could be attributed to the cancer type in a cohort. For example, sepsis was seen in three patients with BTC, and a higher incidence of headache was reported in glioma cohorts. Similarly, a higher incidence of hematological abnormalities was seen in hematological cohorts, even though the incidence of such abnormalities was low.This study has some limitations. It has a non-randomized, single-arm design (per histology). Given the rarity of the tumor types included in the study, it is challenging to design a randomized study for the included cohorts. Although the study collected data for quality of life, these data were not available for most patients. When available, these data were highly variable and did not provide interpretable results. This study did not assess the heterogeneity of the In conclusion, combination treatment with dabrafenib plus trametinib showed meaningful clinical activity in patients with 